- iCrowdNewswire
  • Spain
  • Brazil
  • Russia
  • France
  • Germany
  • China
  • Korea
  • Japan

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Mar 14, 2018 7:40 AM ET

SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Akorn, Inc. (Nasdaq: AKRX) To Contact Brower Piven Before The Lead Plaintiff Deadline

Legal Newswire iCrowdNewswire - Mar 14, 2018

STEVENSON, Md.,  — The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Illinois on behalf of purchasers of Akorn, Inc. (Nasdaq:AKRX) (“Akorn” or the “Company”) securities during the period between March 1, 2017 through February 26, 2018, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until May 7, 2018 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Akorn securities during the Class Period.  Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Akorn’s failure to comply with the U.S. Food and Drug Administration (“FDA”) data integrity requirements would jeopardize Fresenius SE & Co. KGaA’ acquisition of Akorn, and the Company lacked effective internal controls over financial reporting.

According to the complaint, following a February 28, 2018 announcement that the Company was conducting an investigation into alleged breaches of FDA data integrity requirements, the value of Akorn shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Akorn securities purchased on or after March 1, 2017 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.

Contact Information:

Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

View Related News >